Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders
|ClinicalTrials.gov Identifier: NCT00557895|
Recruitment Status : Enrolling by invitation
First Posted : November 14, 2007
Last Update Posted : May 18, 2018
This study will evaluate and follow patients with various allergic, hypersensitivity and inflammatory disorders. The protocol is not designed to test new treatments; patients will be managed with standard of care therapies. Participants may be referred to other current NIAID protocols as appropriate or to new studies as they are developed, but will not be required to join another study.
Patients with allergic, hypersensitivity or inflammatory disorders between the ages of 3 years and 80 years may be eligible for this study. Conditions of interest include, but are not limited to, asthma, allergic rhinitis, mastocytosis, atopic dermatitis and food allergy.
Participants will have a medical history and physical examination, plus standard tests for diagnosing and treating their specific disorder. Tests may include routine blood and urine studies, X-rays or other imaging studies, allergy skin tests and lung function tests. Blood samples may be collected for research on immune system cells and other substances involved in immune function. Generally, about 2 to 6 tablespoons will be drawn at a time, but no more than 16 ounces will be collected over a 6-week period.
NIH does not provide emergency medical treatment or treatment for other, unrelated conditions the patient may have. Therefore, patients must maintain a personal physician for these purposes.
|Condition or disease|
|Allergy Asthma Allergic Rhinitis Mastocytosis Atopic Dermatitis Food Allergy|
|Study Type :||Observational|
|Actual Enrollment :||288 participants|
|Official Title:||Evaluation and Long Term Follow-up of Patients With Allergic and Inflammatory Disorders|
|Study Start Date :||August 26, 1996|
- The protocol serves to evaluate and provide long term follow up of patients with allergic, hypersensitivity and inflammatory disorders for the purposes of maintaining a group of patients from which LAD investigators may draw for other protocols ... [ Time Frame: The outcome is assessed over the time the protocol is active as described elsewhere. ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00557895
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Kelly D Stone, M.D.||National Institute of Allergy and Infectious Diseases (NIAID)|